Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
132 hedge funds and large institutions have $803M invested in Alder Biopharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 62 increasing their positions, 24 reducing their positions, and 23 closing their positions.
158% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 24
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
35% more capital invested
Capital invested by funds: $595M → $803M (+$208M)
22% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 23
3% more funds holding
Funds holding: 128 → 132 (+4)
22% less call options, than puts
Call options by funds: $1.86M | Put options by funds: $2.39M
Top Buyers
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$44.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$18.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.6M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.7M |
| 5 |
PA
Pinnacle Associates
New York
|
+$12.6M |
Top Sellers
ALDR Hedge Fund Activity: Q3 2017 in Review
132 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q3 2017, worth a combined $803M — up 35% from $595M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new ALDR positions and 23 closed out — a net gain of 5 holders — while 62 added to existing stakes and 24 trimmed.
The largest buyer was Redmile Group, adding an estimated $44.3M. The largest seller was Janus Henderson Group, cutting an estimated $22.7M.
- 132 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q3 2017, up from 128 in Q2 2017.
- Funds reported $803M of Alder Biopharmaceuticals stock for Q3 2017, up 35% quarter-over-quarter.
- 28 funds opened new Alder Biopharmaceuticals positions in Q3 2017 and 23 closed out, a net change of +5 holders.
- The largest Alder Biopharmaceuticals buyer in Q3 2017 was Redmile Group, an estimated $44.3M added.
- The largest Alder Biopharmaceuticals seller in Q3 2017 was Janus Henderson Group, an estimated $22.7M sold.
Based on aggregated 13F filings for Q3 2017.